Moreover, the compound exerted its pharmacological impact by targeting the pre-BCR-PI3K signaling pathway that was crucial in MEF2D fusion leukemia cell survival (Figs. 4a, b and 6i). The gene discussed is PIK3CB; the disease is leukemia.